Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amedisys (AMED – Research Report) and Gilead Sciences (GILD – Research Report).
Amedisys (AMED)
In a report released yesterday, Sarah James from Cantor Fitzgerald maintained a Hold rating on Amedisys, with a price target of $101.00. The company’s shares closed last Wednesday at $91.05.
According to TipRanks.com, James is a 5-star analyst with an average return of
Amedisys has an analyst consensus of Hold, with a price target consensus of $100.75, a 10.7% upside from current levels. In a report released today, Truist Financial also maintained a Hold rating on the stock.
See the top stocks recommended by analysts >>
Gilead Sciences (GILD)
Bank of America Securities analyst Geoff Meacham maintained a Buy rating on Gilead Sciences yesterday and set a price target of $95.00. The company’s shares closed last Wednesday at $67.08, close to its 52-week low of $65.90.
According to TipRanks.com, Meacham is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Gilead Sciences with a $84.65 average price target, representing a 27.1% upside. In a report issued on April 11, J.P. Morgan also maintained a Buy rating on the stock with a $95.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AMED:
